EM-652 (SCH57068), a pure SERM in the mammary gland and endometrium

References en Gynecologie Obstetrique

Volumn 8, Issue 5, 2001, Pages 331-336

  Labrie, F ^a   Simard, J ^a   Labrie, C ^a   Belanger A ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

Antiestrogen; Breast cancer; Chemoprevention; EM 652; Estrogen receptor; Osteoporosis; SCH57068; Uterine cancer

Indexed keywords

ACOLBIFENE; ALKALINE PHOSPHATASE; CHOLESTEROL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; RAS PROTEIN; SCH 570687; TAMOXIFEN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BONE ATROPHY; BREAST CANCER; CANCER INHIBITION; CHOLESTEROL BLOOD LEVEL; CONFERENCE PAPER; ENDOMETRIUM; ENZYME ACTIVITY; MAMMARY GLAND; NUDE MOUSE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0035195229     PISSN: 12448168     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (44)

1. Cancer statistics, 2000
2. Estrogen receptors in human breast cancer: An overview
3. Effects of estradiol and prolactin on steroid receptor levels in 7,12-dimethylbenz(a)anthracene-induced mammary tumors and uterus in the rat
4. The role of estrogens in growth regulation of breast cancer
5. Control of aromatase in breast cancer cells and its importance for tumor growth
6. Biology and mode of action of pure antiestrogens
7. Additive inhibitory effects of an androgen and the antiestrogen EM-170 on estradiol-stimulated growth of human ZR-75-1 breast tumors in athymic mice
8. Inhibition of cell cycle kinetics and proliferation by the androgen 5α-dihydrotestosterone and antiestrogen N, n-butyl-N-methyl1 1-(16′ α-chloro-3′, 17β-di hydroxy-estra 1′,3′,5′-(10′)triene-7′ α-yl) undecanamide in human breast cancer ZR-75-1 cells
9. Synthesis and biological activity of new halo-steroidal antiestrogens
10. Mechanisms of antihormone action
11. Novel compounds inhibit estrogen formation and action
12. Inhibitory effect of a steroidal antiestrogen (EM-170) on estrone-stimulated growth of 7,12 dimethylbenz(a)anthracene (DMBA)-induced mammary carcinoma in the rat
13. Human oestrogen receptor cDNA: Sequence, expression and homology to v-erb-A
14. The estrogen receptor binds tightly to its responsive element as a ligand-induced homodimer
15. Tamoxifen for prevention of breast cancer: Report of the national surgical adjuvant breast and bowel project P-I study
16. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of Liver and Endometrial cancer Risk following tamoxifen
17. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation
18. Cloning, chromosomal localization and functional analysis of the murine estrogen receptor β
19. EM-800, a novel antiestrogen, acts as a pure antagonist of the transcriptional functions of estrogen receptors α and β
20. Characterization of the effects of the novel non-steroidal antiestrogen EM-800 on basal and estrogen-induced proliferation of T-47D, ZR-75-1 and MCF-7 human breast cancer cells in vitro
21. Proliferation, hormonal responsiveness, and estrogen receptor content of MCF-7 human breast cancer cells grown in the short-term and long-term absence of estrogens
22. Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse
23. Antiestrogenic properties of keoxifene, trans-4-hydroxytamoxifen and ICI164384, a new steroidal antiestrogen, in ZR-75-1 human breast cancer cells
24. Effects of antioestrogens on the proliferation of MCF-7 human breast cancer cells
25. Effect of estrogens and antiestrogens on cell proliferation and synthesis of secreted proteins in the human breast cancer cell line MCF-7 and tamoxifen resistant variant subline. AL 1
26. Nicholson R1 (1995) Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer
27. Tamoxifen therapy in premenopausal patients with metastatic breast cancer
28. Combined modality therapy for first recurrence of breast cancer. A Southwest Oncology Group study
29. Clinical significance of tamoxifen withdrawal response
30. Tamoxifen as an agonist for metastatic breast cancer
31. Response after withdrawal of tamoxifen and progestogens in advanced breast cancer
32. Tamoxifen resistance in breast cancer
33. MCF7/LCC2: A 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780
34. Anti-proliferative and anti-estrogenic effects of ICI 164,384 and ICI 182,780 in 4-OH-tamoxifen-resistant human breast-cancer cells
35. Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR-1
36. Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens
37. Acquired tamoxifen resistance: Correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen
38. Blockade of the stimulatory effect of estrogens, OH-tamoxifen, OH-toremifene, droloxifene and raloxifene on alkaline phosphatase activity by the antiestrogen EM-800 inhuman endometrial adenocarcinoma Ishikawa cells
39. Prevention of bone loss by EM-800 and Raloxifene in the ovariectomized rat
40. Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer
41. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women
42. Estradiol and tamoxifen interactions with thyroid hormone in the ovariectomized-thyroidectomized rat
43. Droloxifene, a new estrogen antagonist/agonist, prevents bone loss in ovariectomized rats
44. Raloxifene (LY139481 HCl) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats